Skip to content

    Sarepta Therapeutics (SRPT) stock price & financials

    View SRPT earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+15.4% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $467.17M
    $658.41M
    $744.86M
    $611.09M
    $399.36M
    -14.5%
    $442.93M
    -32.7%
    $730.80M
    -1.9%
    $401.25M
    -34.3%
    Weakening
    Operating Profit
    $22.20M
    $161.68M
    -$300.39M
    $115.58M
    -$103.39M
    -565.8%
    -$411.58M
    -354.6%
    $358.43M
    $13.29M
    -88.5%
    Weakening
    Net Profit
    $33.61M
    $159.05M
    -$447.51M
    $196.89M
    -$50.57M
    -250.5%
    -$412.23M
    -359.2%
    $330.96M
    -$4.89M
    -102.5%
    Weakening
    EPS
    $0.35
    $1.65
    $-4.60
    $2.01
    $-0.50
    -242.9%
    $-3.93
    -338.2%
    $3.15
    $-0.05
    -102.5%
    Weakening
    Other Income
    $11.81M
    $10.06M
    -$83.13M
    $38.06M
    -$90.66M
    -867.7%
    $133.29M
    +1224.7%
    -$15.26M
    +81.6%
    -$15.04M
    -139.5%
    Strengthening
    Interest
    $4.92M
    -$23.98M
    -$4.50M
    -$5.23M
    $1.90M
    -61.4%
    -$30.31M
    -26.4%
    -$21.71M
    -382.2%
    -$21.51M
    -311.4%
    Weakening
    Depreciation
    Profit before Tax
    $34.01M
    $171.74M
    -$383.52M
    $153.64M
    -$194.05M
    -670.6%
    -$278.30M
    -262.0%
    $343.17M
    -$1.75M
    -101.1%
    Weakening
    MarginsOPM
    4.8%
    24.6%
    -40.3%
    18.9%
    -25.9%
    -645.1%
    -92.9%
    -478.3%
    49.0%
    3.3%
    -82.5%
    Weakening
    Tax
    1.2%
    7.4%
    -16.7%
    -28.1%
    7.3%
    +526.7%
    -1.6%
    -122.2%
    3.6%
    -179.6%
    -538.0%
    Weakening
    ReturnsROIC
    -0.7%
    -3.5%
    9.8%
    -4.3%
    1.1%
    9.1%
    -7.3%
    -174.0%
    0.1%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$370.83M$835.08M$1.50B$2.12B$966.78M$428.43M$1.10B$801.28M$571.15M
    Short-Term Investments
    Total Current Assets$1.43B$1.47B$2.49B$2.60B$2.56B$2.58B$3.07B$2.54B$2.22B
    Net PP&E$97.02M$167.55M$282.19M$236.69M$244.99M$357.11M$488.65M$470.62M$446.84M
    Goodwill
    Intangibles$11.57M$12.50M$13.63M$14.24M$7.58M$29.62M$26.89M$28.95M$30.61M
    Total Assets$1.64B$1.82B$2.98B$3.15B$3.13B$3.26B$3.96B$3.35B$3.19B
    LiabilitiesTotal Current Liabilities$173.69M$264.77M$416.03M$452.73M$619.60M$653.66M$731.68M$1.10B$502.91M
    Short-Term Debt$0$105.48M$0
    Long-Term Debt$420.55M$563.67M$1.54B$1.24B$1.14B$828.97M$847.62M
    Long-Term Leases$47.72M$80.37M$41.51M$57.58M$140.97M$192.47M$199.38M$198.23M
    Total Liabilities$609.80M$1.00B$2.22B$2.22B$2.74B$2.41B$2.44B$2.21B$1.66B
    EquityCommon Stock & APIC$7.0K$8.0K$8.0K$9.0K$9.0K$9.0K$10.0K$11.0K$11.0K
    Retained Earnings-$1.58B-$2.29B-$2.85B-$3.21B-$3.91B-$4.45B-$4.21B-$4.88B-$4.55B
    Total Equity$1.03B$818.19M$761.76M$928.01M$384.95M$859.34M$1.53B$1.14B$1.53B
    HighlightsNet Cash / (Debt)-$577.51M-$915.05M-$34.11M

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$388.66M-$456.46M$107.47M-$443.17M-$325.35M-$500.99M-$205.79M-$205.48M$111.01M
    Cash from Investing-$370.49M$286.73M-$121.72M$495.41M-$1.05B-$165.80M$755.56M$69.64M$100.84M
    Cash from Financing$530.15M$642.55M$682.32M$561.57M$232.51M$125.00M$124.81M-$168.34M-$156.76M
    SummaryCapital Expenditure-$61.16M-$59.63M-$82.20M-$38.49M-$30.82M-$76.11M-$136.96M-$101.97M-$29.16M
    Free Cash Flow-$449.82M-$516.09M$25.26M-$481.66M-$356.17M-$577.10M-$342.74M-$307.45M$81.85M
    FCF Margin-149.4%-135.5%4.7%-68.6%-38.2%-46.4%-18.0%-14.0%4.1%

    Ratios